Dyne Therapeutics’ (DYN) “Buy” Rating Reaffirmed at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $46.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 276.80% from the company’s current price.

A number of other research analysts have also recently commented on DYN. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Chardan Capital restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday. Finally, Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.85.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded up $0.16 during mid-day trading on Monday, hitting $12.21. 706,976 shares of the company’s stock traded hands, compared to its average volume of 1,328,662. The company has a market capitalization of $1.38 billion, a P/E ratio of -3.43 and a beta of 1.11. Dyne Therapeutics has a 1 year low of $11.18 and a 1 year high of $47.45. The company’s 50-day moving average is $14.58 and its two-hundred day moving average is $25.13.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. Equities analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 6,237 shares of company stock worth $77,760. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors have recently modified their holdings of DYN. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE grew its holdings in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics during the 4th quarter worth about $50,000. Finally, KBC Group NV raised its holdings in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.